HCW Biologics Inc. has taken a significant step in its financial strategy by entering into a Notes Purchase Agreement with Streeterville Capital, LLC. This agreement, finalized on November 3, 2026, provides the company with $10.2 million through two secured promissory notes. This funding is expected to enhance HCW's clinical development programs and support its strategic business initiatives.

The company, based in Miramar, Florida, operates within the pharmaceutical preparations sector, as indicated by its Standard Industrial Classification (SIC) code 2834. As an emerging growth company listed on the Nasdaq under the ticker HCWB, HCW Biologics focuses on developing innovative biologic therapies.

According to the recent SEC filing (accession number 0001493152-26-050082), the agreement includes two notes: Promissory Note A-1 for $3.2 million and Promissory Note B for $7.0 million. Notably, the A-1 Note carries an original issue discount of $240,000, and the company has agreed to pay $30,000 to cover the lender's transaction costs, which is included in the A-1 Note's principal balance.

The closing of this agreement occurred on November 4, 2026, with the lender providing $3.0 million after transaction costs. An additional $7.0 million has been deposited into an account of HCW's newly formed subsidiary, HCWB Holdings, LLC, under a Deposit Account Control Agreement. The funds are intended to support HCW's clinical development programs and other corporate purposes.

Each time the aggregate outstanding balance of all A Notes is reduced by $1.0 million, HCW will have the option to exchange $750,000 of the B Note for a new note similar to the A-1 Note. This flexibility in financing could aid the company in managing its debt more effectively.

Maxim Group LLC served as the placement agent for this transaction, receiving a 7% cash fee on the gross proceeds. The agreement also includes provisions for reimbursement of out-of-pocket expenses, including legal fees, not exceeding $30,000.

The principal amount of the A-1 Note, along with accrued interest, is due within 24 months of issuance, with an interest rate of 8% per annum. The company retains the option to prepay the A-1 Note, subject to a 10% prepayment premium. Additionally, if the A-1 Note remains outstanding for 90 days post-closing, a one-time monitoring fee will be added to the outstanding balance, which can be forgiven under certain conditions.

This funding initiative by HCW Biologics could significantly impact its operational capabilities and competitive stance within the pharmaceutical preparations industry. As the company moves forward with its clinical and strategic development, the industry will be keenly observing its progress and the potential outcomes of this financial maneuver.

The filing does not specify what happens next, but the successful execution of this agreement marks a crucial step in HCW's ongoing development efforts.